D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.00 price objective on the stock.

VNRX has been the topic of a number of other research reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research report on Thursday, January 23rd. They issued a “sell” rating on the stock.

VolitionRx Stock Up 2.9 %

VolitionRx stock opened at $0.63 on Wednesday. The firm has a market cap of $57.92 million, a P/E ratio of -1.74 and a beta of 1.20. The business has a fifty day moving average of $0.63 and a two-hundred day moving average of $0.66. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.